A fragment of the envelope protein from dengue‐1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Biotechnology and applied biochemistry

• Publication date

  2004-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1042/BA20030039PMID 12887334
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prolonged presence of effector‐memory CD8 T cells in the central nervous system after dengue virus encephalitis

  2003cited by this paper
• A recombinant envelope protein from Dengue virus purified by IMAC is bioequivalent with its immune-affinity chromatography purified counterpart.

  2002cited by this paper
• Dengue: an update.

  2002cited by this paper
• Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers

  2001cited by this paper
• Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine.

  2001cited by this paper
• Molecular Cloning: A Laboratory Manual

  2001cited by this paper
• Chimeric Yellow Fever/Dengue Virus as a Candidate Dengue Vaccine: Quantitation of the Dengue Virus-Specific CD8 T-Cell Response

  2000cited by this paper
• PrM- and Cell-Binding Domains of the Dengue Virus E Protein

  1999cited by this paper
• Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice.

  1998cited by this paper
• A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial.

  1998cited by this paper
• [Cholecystectomy in respiratory insufficiency: role of laparoscopy with abdominal lift].

  1998cited by this paper
• Expression of the dengue virus structural proteins in Pichia pastoris leads to the generation of virus-like particles.

  1997cited by this paper
• Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice.

  1997cited by this paper
• Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection.

  1995cited by this paper
• Flavivirus type-specific antigens produced from fusions of a portion of the E protein gene with the Escherichia coli trpE gene.

  1991cited by this paper
• Japanese Encephalitis Virus Fusion Protein with Protein A Expressed in Escherichia coli Confers Protective Immunity in Mice

  1991cited by this paper
• Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis

  1990cited by this paper
• Flavivirus genome organization, expression, and replication.

  1990cited by this paper
• Protein measurement using bicinchoninic acid: elimination of interfering substances.

  1989cited by this paper
• Structure of the Flavivirus Genome

  1986cited by this paper
• Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization

  1985cited by this paper
• Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

  1979cited by this paper
• Isolation of a Singh's Aedes albopictus cell clone sensitive to Dengue and Chikungunya viruses.

  1978cited by this paper
• DNA sequencing with chain-terminating inhibitors.

  1977cited by this paper
• Complementary specificity of restriction endonucleases of Diplococcus pneumoniae with respect to DNA methylation.

  1977cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses.

  1958cited by this paper

• Advancements in dengue vaccines: A historical overview and pro-spects for following next-generation candidates.

  2025cites this paper
• Synthesis, LC-MS/MS analysis, and biological evaluation of two vaccine candidates against ticks based on the antigenic P0 peptide from R. sanguineus linked to the p64K carrier protein from Neisseria meningitidis

  2021cites this paper
• Dengue fever: Causes, complications, and vaccine strategies – A review

  2019cites this paper
• Dengue viruses and promising envelope protein domain III-based vaccines

  2018cites this paper
• Dengue Fever: Causes, Complications, and Vaccine Strategies

  2016cites this paper
• Dengue vaccine: an update on recombinant subunit strategies.

  2016cites this paper
• A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice

  2014cites this paper
• Dengue virus type-3 envelope protein domain III; expression and immunogenicity

  2014cites this paper
• Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus

  2014cites this paper
• Experimental Dengue Vaccines

  2013cites this paper
• Virus-like particles as nanovaccine candidates

  2013cites this paper
• Treinta años después de la epidemia cubana de dengue hemorrágico en 1981

  2012cites this paper
• Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2.

  2012cites this paper
• Thirty years after the Cuban hemorrhagic dengue epidemic of 1981.

  2012cites this paper
• A vaccine formulation consisting of nucleocapsid-like particles from Dengue-2 and the fusion protein P64k-domain III from Dengue-1 induces a protective immune response against the homologous serotypes in mice.

  2012cites this paper
• The Chimeric Protein Domain III-Capsid of Dengue Virus Serotype 2 (DEN-2) Successfully Boosts Neutralizing Antibodies Generated in Monkeys upon Infection with DEN-2

  2011cites this paper
• Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2

  2011cites this paper
• Domain III of the envelope protein as a dengue vaccine target

  2010cites this paper
• Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies.

  2010cites this paper
• Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use.

  2010cites this paper
• Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses.

  2010cites this paper
• Dengue: recent advances in biology and current status of translational research.

  2009cites this paper
• A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice.

  2009cites this paper
• Comparative immunogenicity and protective capacity of two Dengue-4 vaccine candidates based on P64k-envelope domain III

  2009cites this paper
• Dengue‐4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice

  2009cites this paper
• An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.

  2009cites this paper
• An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes.

  2008cites this paper
• Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus.

  2008cites this paper
• Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates.

  2008cites this paper
• Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells.

  2008cites this paper
• Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific Neutralizing Antibodies to Dengue Virus

  2007cites this paper
• Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice.

  2006cites this paper
• A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates.

  2006cites this paper
• Instituto de Medicina Tropical

  2005cites this paper
• Dengue, Vaccination and Vector Control

  2005cites this paper
• Dengue vaccine: priorities and progress

  2004cites this paper